Why does our ID have to be scanned at every room @AASLDtweets at the liver meeting? Are we being tracked? Delays entry to rooms. What happens to these data? #lossofprivacy #bigbrother #TLM
English
Adrian Di Bisceglie
1.1K posts
Adrian Di Bisceglie
@dibiscam
Professor of Internal Medicine at Saint Louis University. Co-Director of the Saint Louis University Liver Center. Past President of AASLD. (@AASLDNews)
St. Louis, MO Katılım Kasım 2013
290 Takip Edilen1.3K Takipçiler
Adrian Di Bisceglie retweetledi
If you want to know how it’s going in the ER, last night I saw more patients than I’ve ever seen in a single night shift in my entire career. And I’ve been out of residency since 2005, working only night shifts since 2006.
English
Adrian Di Bisceglie retweetledi
Thank you @NatRevGastroHep for highlighting our paper on #NASH drugs. @NoureddinMD @RajVlanchi @dibiscam @JonathanStineMD @Pinnacle_TX @LiverArizona @MadrigalPharma @novonordiskus @InterceptPharma @InventivaPharma
Nature Reviews Gastroenterology & Hepatology@NatRevGastroHep
Best of 2021 - CITATIONS No.7 is this REVIEW on the therapeutic pipeline in nonalcoholic steatohepatitis Vuppalanchi, @NoureddinMD, @AlkhouriNaim & Sanyal nature.com/articles/s4157… read-only link rdcu.be/cC7Ie #NASH #NAFLD #MAFLD
English
Adrian Di Bisceglie retweetledi
Congratulations to our Director, Dr. Lorne Tyrrell, on receiving @HepBFoundation's 2022 Blumberg Prize for his pioneering work on hepatitis B!
Hep B Foundation@HepBFoundation
Congratulations to Dr. Lorne Tyrrell. NEWS RELEASE: Canadian scientist chosen for the 2022 #HepatitisB Foundation’s Blumberg Prize. Dr. Lorne Tyrell of the @UAlberta is among the pioneers of therapeutic agents to treat chronic hepatitis B. ow.ly/x2I350GThOw @UAlberta_FoMD
English
Adrian Di Bisceglie retweetledi
Great news! Our oral presentation about HTD1801 results in patients w/ #NASH & #diabetes has been selected as one of the ‘Best of The Liver Meeting’ 2021 by @AASLDtweets! Exciting to see the data showcased during closing remarks today. #TLMdX #livertwitter
twitter.com/HighTideThera/…
HighTide Therapeutics@HighTideThera
Liver fat content w/ HTD1801 (Berberine Ursodeoxycholate) closely associated with improved glycemic control, weight loss & reduced ALT in patients w/ #NASH? #TLMdX @AASLDtweets #livertwitter ow.ly/AHXy50GMs1e
English
Adrian Di Bisceglie retweetledi
Very honored to be in this lineup of brilliant women, summarizing the inspiring work of our community! What a meeting! @CarlaBradyMD @Duke_liverdoc @AASLDtweets @AASLDPresident
Vivian Ortiz@VivianOrtizMD
It is that time for the debriefs! Happening now @heatherleefran for basic science @elizabeth_verna on clinical hepatology, @CarlaBradyMD on Hepatitis and @Duke_liverdoc on NAFLD #LiverMtg21 #LiverTwitter
English
Adrian Di Bisceglie retweetledi
Thank you @ruthanne_pai for highlighting the excellent session Emerging Therapies for #PSC & #PBC. Thanks to @DrCynthiaLevy & @AutoImmuneLiver. #LiverMtg21 @AASLDtweets @EASLnews @PSCPartners @PSCPartnersCa @PSCSupportUK @pscsupportau @EuropeLiver @ERN_RARE_LIVER @blackingastro
Ruth-Anne Pai, PhD@ruthanne_pai
WOW! So many lessons from @DrCynthiaLevy and @AutoImmuneLiver's session on emerging therapies for PSC ⭐️Think beyond ALP in PSC ⭐️Think OUTSIDE the box of just repositioning strategies from PBC ⭐️Stratify and learn WHO to recruit to RCTs ⭐️Move towards combination therapy #TLMdX
English
Adrian Di Bisceglie retweetledi
More HTD1801 #NASH results: 18 weeks of treatment w/ Berberine Ursodeoxycholate in subjects w/ NASH & Type 2 #Diabetes was associated w/ improvements in some non-invasive fibrosis markers. Check out our #TLMdX poster (1191) for more. #livertwitter ow.ly/KXF550GMskc
English
Adrian Di Bisceglie retweetledi
More HTD1801 #PSC results: 18 weeks of treatment by those previously exposed to UDCA improved biochemical markers of cholestasis & liver injury. Check out our #TLMdX poster presentation (1267) for details. @AASLDtweets #livertwitter ow.ly/p23e50GMsg0
English
Adrian Di Bisceglie retweetledi
Liver fat content w/ HTD1801 (Berberine Ursodeoxycholate) closely associated with improved glycemic control, weight loss & reduced ALT in patients w/ #NASH? #TLMdX @AASLDtweets #livertwitter ow.ly/AHXy50GMs1e
English
Adrian Di Bisceglie retweetledi
How did our main candidate HTD1801 (Berberine Ursodeoxycholate) perform in patients w/ Primary Sclerosing Cholangitis (#PSC) not previously exposed to UDCA? #TLMdX @AASLDtweets #livertwitter
ow.ly/uCbQ50GMlGh
English
Adrian Di Bisceglie retweetledi
Summary slide of NAFLD screening pathways by @QAnstee ; clear that 2 step screening strategy important. #TLMDx #LiverMtg21 #LiverTwitter
English
Adrian Di Bisceglie retweetledi
Ask anyone with a chronic illness: It takes long-term patience to be a long-term patient. Read more about the #PSC experience on the @PSCPartners blog. #PSCAware #livertwitter ow.ly/Wv6Y50GAOZY
English
Adrian Di Bisceglie retweetledi
How are we hoping to help #PSC patients manage their chronic liver condition? By developing a well-tolerated drug for the difficult-to-treat #raredisease, which currently has no approved therapy. Check out the latest clinical trial results: ow.ly/x4fa50GAP2q #PSCAware
English
Adrian Di Bisceglie retweetledi
New Phase II data is coming! We're excited to be presenting the latest clinical findings in our evaluations of HTD1801 in patients w/ primary sclerosing cholangitis (#PSC) & #NASH at this month's #TLMdX Liver Meeting. Stay tuned for details. #livertwitter
ow.ly/F7LN50GGboQ
English
Adrian Di Bisceglie retweetledi
Thanks @dibiscam , Drs. Bruce Luxon & Jason Taylor for organizing a memorable retirement party for Dr. Bruce Bacon. It was a great opportunity to celebrate a brilliant career and legacy of Dr. Bacon @slusom @SLUHospital @slucare @SLUgastro
English
Adrian Di Bisceglie retweetledi
Excited to see our recent publication highlighted as a Featured Article on @NatureComms!
Read more about Phase II results of HTD1801 in patients with #NASH and #diabetes in this paper by @dibiscam et al: ow.ly/CxKN50GdYYo
English
Adrian Di Bisceglie retweetledi
Y’all, our #COVID ICU unit is full. All of our ICUs are full. All of our ICU teams are flooded. Our ED is packed. We are turning away hospital transfers because there isn’t room. The #DeltaVariant is real. Masks work. Vaccines are safe and effective. Please get your vaccine!
GIF
Birmingham, AL 🇺🇸 English
Pleased to be attending #2021NASHTAG in person in beautiful Park City UT. My first live conference in more than a year! So great to see friends and colleagues again
English